Semaglutide single‐dose pen‐injector: Post hoc analysis of summative usability testing for weight management-Reference-Cited by-同舟云学术

Semaglutide single‐dose pen‐injector: Post hoc analysis of summative usability testing for weight management

Published:2021-08-31 Issue:11 Volume:23 Page:2590-2594
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Klonoff David C.¹^ORCID,Bassock Stephanie²,Engels Ella³,Frederiksen Marie⁴,Marber Matthew³,Qvist Marianne⁴,Sparre Thomas⁴,Snitker Søren⁴^ORCID

Affiliation:

1. Mills‐Peninsula Medical Center San Mateo California USA

2. Emergo by UL Chicago Illinois USA

3. Emergo by UL Concord Massachusetts USA

4. Novo Nordisk A/S Søborg Denmark

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14509

Reference7 articles.

1. U.S. Food and Drug AdministrationFDA approves new drug treatment for chronic weight management first since 2014.https://www.fda.gov/news‐events/press‐announcements/fda‐approves‐new‐drug‐treatment‐chronic‐weight‐management‐first‐2014. Accessed August 24 2021.

2. Evolution of Diabetes Insulin Delivery Devices

3. Novo NordiskOzempic® (semaglutide) summary of product characteristics. 2018.https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004174/WC500244163.pdf. Accessed August 24 2021.

4. Novo NordiskOzempic® (semaglutide) prescribing information. 2019.https://www.novo-pi.com/ozempic.pdf. Accessed August 24 2021.

5. Evaluating the usability and safety of the semaglutide single‐dose pen‐injectors through summative (human factors) usability testing

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Semaglutide and Empagliflozin on Pulmonary Structure and Proteomics in Obese Mice;Diabetes, Metabolic Syndrome and Obesity;2024-03

2. Effects of Semaglutide on Cardiac Protein Expression and Cardiac Function of Obese Mice;Journal of Inflammation Research;2022-11

3. Ease‐of‐use and acceptability of the novel semaglutide 2.4 mg single‐dose pen‐injector in people with overweight or obesity in the STEP 8 phase III trial;Diabetes, Obesity and Metabolism;2022-08-07

4. Metformin Inhibits Lipid Droplets Fusion and Growth via Reduction in Cidec and Its Regulatory Factors in Rat Adipose-Derived Stem Cells;International Journal of Molecular Sciences;2022-05-26

5. Comparison of the injection‐site experience of semaglutide in a single‐dose and a multidose pen‐injector;Diabetes, Obesity and Metabolism;2022-05-20